CD274 and non-small cell lung carcinoma: First, we utilized the most detailed clinical efficacy and safety data regarding first-line Pembro+Chemo and Pembro to describe the cost-effectiveness of these two widely used and controversial treatments for non-squamous and squamous NSCLC patients with PD-L1 expression ≥50%, respectively.